市場調査レポート

商品コード

1304161

糖尿病性胃不全麻痺治療市場：製品タイプ別、適応疾患別、流通チャネル別、地域別：市場規模、シェア、展望、機会分析、2023年～2030年

Diabetic Gastroparesis Treatment Market, By Product Type (Drugs, Surgical Treatment Products ), By Disease Indication, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日: 2023年05月30日 | 発行: Coherent Market Insights

| ページ情報: 英文 170 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 697,230円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,084,580円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,549,400円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=154.94円

全表示
概要
目次

概要

サンプル依頼リストに入れる

胃不全麻痺は、機械的な閉塞を認めない胃排出の遅延です。糖尿病性胃不全麻痺は、自律神経系、神経細胞、胃および腸の特殊なペースメーカー細胞、消化管の平滑筋細胞の協調および機能障害に起因する、コントロール不良の糖尿病の設定で発生する潜在的な合併症です。糖尿病性胃不全麻痺は、自律神経系および腸管神経系の機能障害の結果として起こる。慢性的な高血糖（または非効率的なグルコース取り込み）が神経細胞障害を引き起こし、その結果、腸管神経伝達の異常、抑制性神経細胞機能の低下、胃の平滑筋およびペースメーカー細胞の機能不全が生じる。

この機能障害により、肛門の収縮が減少し、肛門-十二指腸の収縮が協調しなくなり、幽門の痙攣が起こり、最終的に胃排出遅延（胃不全麻痺）が起こる。糖尿病患者における胃排出遅延、特に固形物の排出遅延は、小腸の運動異常でも起こる可能性があり、これは胃で説明したのと同様のメカニズムで起こると考えられています。糖尿病患者の中には、さらに胃コンプライアンスの亢進または低下という変化を経験する場合があり、これも胃排出遅延の一因となっている可能性があります。

市場力学

世界の糖尿病有病率の増加、老年人口の増加と座りがちなライフスタイルの増加、患者の薬物治療に対する手頃な価格と入手しやすさの向上、糖尿病性胃不全麻痺に関する研究開発活動が、世界の糖尿病性胃不全麻痺治療市場の成長に寄与しています。例えば、2020年6月23日、米国を拠点とする製薬会社Evoke Pharma社は、米国食品医薬品局（FDA）が、急性および再発性の糖尿病性胃不全麻痺の成人の症状を緩和するGimoti点鼻スプレーの新薬申請を承認したと発表しました。メトクロプラミドという薬剤は、副作用を伴うため使用が限られています。そこで、経鼻的に薬剤を導入するという新しいアプローチがとられました。

研究の主な特徴

本レポートは、糖尿病性胃不全麻痺治療の世界市場を詳細に分析し、2022年を基準年とした予測期間（2023-2030年）の市場規模および複合年間成長率（CAGR）を提供します。
また、さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場に対する魅力的な投資提案のマトリックスについて解説しています。
また市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
以下のパラメータ-企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略-に基づいて、世界の糖尿病性胃不全症市場における主要企業をプロファイルしています。
本調査の対象となる主要企業には、Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc.（Becton, Dickinson and Company）, Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.が含まれます。
本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
世界の糖尿病性胃不全麻痺治療市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
利害関係者は、世界の糖尿病性胃不全麻痺治療市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

北米
米国
カナダ
ラテンアメリカ
ブラジル
メキシコ
アルゼンチン
その他ラテンアメリカ
欧州
英国
ドイツ
イタリア
フランス
スペイン
ロシア
その他欧州
アジア太平洋
中国
インド
日本
ASEAN
オーストラリア
韓国
その他アジア太平洋地域
中東
GCC
イスラエル
その他中東
アフリカ
北アフリカ
中央アフリカ
南アフリカ

第9章競合情勢

Janssen Global Services, LLC
Cardinal Health, Inc.
Evoke Pharma, Inc.
Salix Pharmaceuticals, Inc.
Alfa Wassermann SPA
Abbott Laboratories
Medtronic Plc
C.R. Bard, Inc.（Becton, Dickinson and Company）
Rhythm Pharmaceuticals, Inc.
Boston Scientific Corporation
Kimberly-Clark Corporation.
Vanda Pharmaceuticals, Inc.
Allergan, plc.

第10章セクション

調査手法
出版社について

Product Code: CMI3603

Gastroparesis is the delaying of gastric emptying without any evidence of mechanical obstruction. Diabetic gastroparesis is a potential complication that occurs in the setting of poorly controlled diabetes, resulting from dysfunction in the coordination and function of the autonomic nervous system, neurons, and specialized pacemaker cells of the stomach and intestine, and the smooth muscle cells of the gastrointestinal tract. Diabetic gastroparesis occurs as a result of dysfunction in the autonomic and enteric nervous systems. Chronically high levels of blood glucose (or inefficient glucose uptake) lead to neuronal damage resulting in abnormal myenteric neurotransmission, impaired inhibitory neuronal function, and dysfunctional smooth muscle and pacemaker cells of stomach.

Altogether, this dysfunction results in a combination of fewer contractions of the antrum, uncoordinated antro-duodenal contractions, and pyloric spasms, ultimately resulting in delayed gastric emptying (gastroparesis). Delayed gastric emptying in patients with diabetes, particularly of solids, may also occur in the setting of abnormal small bowel motility, which is thought to occur by a similar mechanism as that which is described in the stomach. Some patients with diabetes may additionally experience changes in gastric compliance, both increased or decreased, which may also contribute to delayed gastric emptying.

Market Dynamics

Increasing prevalence of diabetes worldwide, increasing geriatric population and sedentary lifestyle, increasing affordability and accessibility of medication to patients, and research and development activities on diabetic gastroparesis attributed to the growth of global diabetic gastroparesis treatment market. For instance, on June 23, 2020, Evoke Pharma, a U.S.-based pharmaceutical company, announced that the U.S. Food And Drug Administration has approved the new drug application for Gimoti nasal spray to relieve symptoms in adults with acute and recurrent diabetic gastroparesis. The drug, Metoclopramide has limited use due to associated side effects. Hence, a novel approach by introducing drug in trans nasal pathway is taken.

Key features of the study:

This report provides an in-depth analysis of the Global Diabetic Gastroparesis Treatment Market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global diabetic gastroparesis market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global diabetic gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic gastroparesis treatment market

Detailed Segmentation:

Global Diabetic Gastroparesis Treatment Market, By Product Type:
- Drugs
  - Gastroprokinetic Agents
  - Antiemetic Agents
  - Botulinum Toxin
- Surgical Treatment Products
  - Gastric Electrical Stimulation (GES) Device
  - Percutaneous Endoscopic Gastrostomy (PEG) Kit
  - Parenteral Nutrition
Global Diabetic Gastroparesis Treatment Market, By Disease Indication:
- Compensated Gastroparesis
- Gastric Failure
Global Diabetic Gastroparesis Treatment Market, By Distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Diabetic Gastroparesis Treatment Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Janssen Global Services *
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- LLC, Cardinal Health, Inc.
- Evoke Pharma, Inc.
- Salix Pharmaceuticals, Inc.
- Alfa Wassermann SPA
- Abbott Laboratories
- Medtronic Plc.,
- C.R. Bard, Inc. (Becton, Dickinson and Company)
- Rhythm Pharmaceuticals, Inc.
- Boston Scientific Corporation
- Kimberly-Clark Corporation
- Vanda Pharmaceuticals, Inc.
- Allergan, plc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Diabetic Gastroparesis Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Diabetic Gastroparesis Treatment Market, By Product Type, 2018 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Gastroprokinetic Agents
Antiemetic Agents
Botulinum Toxin
Surgical Treatment Products
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment trends
Gastric Electrical Stimulation (GES) Device
Percutaneous Endoscopic Gastrostomy (PEG) Kit
Parenteral Nutrition

6. Global Diabetic Gastroparesis Treatment Market, By Disease Indication, 2018 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Compensated Gastroparesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Gastric Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

7. Global Diabetic Gastroparesis Treatment Market, By Distribution channel, 2018 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

8. Global Diabetic Gastroparesis Treatment Market, By Region, 2018 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018- 2030, (US$ Million)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Janssen Global Services, LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Cardinal Health, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Evoke Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Salix Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Alfa Wassermann SPA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Medtronic Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
C.R. Bard, Inc. (Becton, Dickinson and Company)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Rhythm Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Boston Scientific Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Kimberly-Clark Corporation.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Vanda Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Allergan, plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

10. Section

Research Methodology
About Us

糖尿病性胃不全麻痺治療市場：製品タイプ別、適応疾患別、流通チャネル別、地域別：市場規模、シェア、展望、機会分析、2023年～2030年

Diabetic Gastroparesis Treatment Market, By Product Type (Drugs, Surgical Treatment Products ), By Disease Indication, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

市場力学

研究の主な特徴

目次

第1章調査目的と前提条件

第2章市場概況

第3章市場力学、規制、動向分析

第4章糖尿病性胃不全麻痺治療の世界市場：コロナウイルス（COVID-19）パンデミックの影響

第5章糖尿病性胃不全麻痺治療の世界市場：製品タイプ別、2018年～2030年

第6章糖尿病性胃不全麻痺治療の世界市場：疾患適応別、2018年～2030年

第7章糖尿病性胃不全麻痺治療薬の世界市場：流通チャネル別、2018年～2030年

第8章糖尿病性胃不全麻痺治療薬の世界市場：地域別、2018年～2030年

第9章競合情勢

第10章セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Diabetic Gastroparesis Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

5. Global Diabetic Gastroparesis Treatment Market, By Product Type, 2018 - 2030, (US$ Million)

6. Global Diabetic Gastroparesis Treatment Market, By Disease Indication, 2018 - 2030, (US$ Million)

7. Global Diabetic Gastroparesis Treatment Market, By Distribution channel, 2018 - 2030, (US$ Million)

8. Global Diabetic Gastroparesis Treatment Market, By Region, 2018 - 2030, (US$ Million)

9. Competitive Landscape

10. Section

糖尿病性胃不全麻痺治療市場：製品タイプ別、適応疾患別、流通チャネル別、地域別：市場規模、シェア、展望、機会分析、2023年～2030年

Diabetic Gastroparesis Treatment Market, By Product Type (Drugs, Surgical Treatment Products ), By Disease Indication, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

市場力学

研究の主な特徴

目次

第1章 調査目的と前提条件

第2章 市場概況

第3章 市場力学、規制、動向分析

第4章 糖尿病性胃不全麻痺治療の世界市場：コロナウイルス（COVID-19）パンデミックの影響

第5章 糖尿病性胃不全麻痺治療の世界市場：製品タイプ別、2018年～2030年

第6章 糖尿病性胃不全麻痺治療の世界市場：疾患適応別、2018年～2030年

第7章 糖尿病性胃不全麻痺治療薬の世界市場：流通チャネル別、2018年～2030年

第8章 糖尿病性胃不全麻痺治療薬の世界市場：地域別、2018年～2030年

第9章 競合情勢

第10章 セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Diabetic Gastroparesis Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

5. Global Diabetic Gastroparesis Treatment Market, By Product Type, 2018 - 2030, (US$ Million)

6. Global Diabetic Gastroparesis Treatment Market, By Disease Indication, 2018 - 2030, (US$ Million)

7. Global Diabetic Gastroparesis Treatment Market, By Distribution channel, 2018 - 2030, (US$ Million)

8. Global Diabetic Gastroparesis Treatment Market, By Region, 2018 - 2030, (US$ Million)

9. Competitive Landscape

10. Section

第1章調査目的と前提条件

第2章市場概況

第3章市場力学、規制、動向分析

第4章糖尿病性胃不全麻痺治療の世界市場：コロナウイルス（COVID-19）パンデミックの影響

第5章糖尿病性胃不全麻痺治療の世界市場：製品タイプ別、2018年～2030年

第6章糖尿病性胃不全麻痺治療の世界市場：疾患適応別、2018年～2030年

第7章糖尿病性胃不全麻痺治療薬の世界市場：流通チャネル別、2018年～2030年

第8章糖尿病性胃不全麻痺治療薬の世界市場：地域別、2018年～2030年

第9章競合情勢

第10章セクション